Glenview Trust co Sells 2,149 Shares of Humana Inc. $HUM

Glenview Trust co lowered its position in Humana Inc. (NYSE:HUM) by 5.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 38,329 shares of the insurance provider’s stock after selling 2,149 shares during the period. Glenview Trust co’s holdings in Humana were worth $9,371,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Humana by 1.6% in the second quarter. Vanguard Group Inc. now owns 14,199,096 shares of the insurance provider’s stock worth $3,471,395,000 after purchasing an additional 226,224 shares during the period. Dodge & Cox boosted its holdings in shares of Humana by 5.6% during the 2nd quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock valued at $2,775,562,000 after buying an additional 597,705 shares in the last quarter. State Street Corp boosted its holdings in shares of Humana by 1.1% during the 2nd quarter. State Street Corp now owns 5,377,390 shares of the insurance provider’s stock valued at $1,319,334,000 after buying an additional 58,094 shares in the last quarter. Pzena Investment Management LLC grew its position in shares of Humana by 6.5% in the 2nd quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider’s stock worth $996,664,000 after buying an additional 247,744 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Humana by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 3,130,829 shares of the insurance provider’s stock worth $762,233,000 after acquiring an additional 57,267 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Trading Up 2.4%

Shares of NYSE HUM opened at $256.29 on Thursday. The firm’s 50 day moving average price is $262.53 and its 200-day moving average price is $257.71. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $315.35. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 2.02. The company has a market cap of $30.82 billion, a PE ratio of 24.02, a P/E/G ratio of 1.47 and a beta of 0.46.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.29. The company had revenue of $32.65 billion during the quarter, compared to the consensus estimate of $31.99 billion. Humana had a net margin of 1.02% and a return on equity of 12.86%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the firm earned $4.16 earnings per share. On average, equities research analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be paid a $0.885 dividend. The ex-dividend date is Friday, December 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.4%. Humana’s payout ratio is currently 33.18%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HUM. The Goldman Sachs Group lowered their price target on shares of Humana from $235.00 to $215.00 and set a “sell” rating for the company in a research report on Monday, November 24th. Royal Bank Of Canada raised their target price on shares of Humana from $283.00 to $322.00 and gave the company an “outperform” rating in a research note on Thursday, August 21st. Mizuho boosted their price target on Humana from $300.00 to $345.00 and gave the stock an “outperform” rating in a research report on Thursday, October 9th. Wolfe Research cut their price target on Humana from $313.00 to $300.00 and set an “outperform” rating on the stock in a research note on Thursday, November 20th. Finally, Barclays reduced their price objective on Humana from $245.00 to $234.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 25th. Nine equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $296.84.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.